SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Biotech Valuation -- Ignore unavailable to you. Want to Upgrade?


To: DewDiligence_on_SI who wrote (51010)7/29/2019 3:11:39 PM
From: A.J. Mullen1 Recommendation

Recommended By
DewDiligence_on_SI

  Read Replies (1) | Respond to of 52153
 
Agreed, but even allowing for a 10% rise pre-announcement, an overall 15% premium that’s paid mostly in stock seems less than exciting to me. Granted EXAS has a better-looking chart than GHDX, but I’ve always liked Genomic’s story and I don’t see the fit between a screening company and one used to determine treatment in oncology.